Stockscreener 앱 받기
131.06
0.68%
-0.90
시간 외 거래:
134.00
2.94
+2.24%
Repligen Corp 주식(RGEN)의 최신 뉴스
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Repligen Corp|Price:131.970|Chg%:-5.630 - TradingKey
RGEN|Repligen Corp|Price:130.951|Chg%:-1.009 - TradingKey
Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story! - Smartkarma
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Daily Brief Health Care: Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Akeso, Mitesco Inc, Nagaileben, Repligen Corp, Scribe Therapeutics, Cosmos Health and more - Smartkarma
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research
Canaccord reiterates Hold on Repligen stock after BioLife deal By Investing.com - Investing.com India
RGEN stock holds steady as Repligen backs 2026 growth - Ad-hoc-news.de
Canaccord reiterates Hold on Repligen stock after BioLife deal - Investing.com
Bothell firm fetches $1.5 billion in acquisition by Massachusetts company - The Business Journals
Repligen to Acquire BioLife Solutions for $1.5 Billion, Expanding Leadership in Cell Therapy Market - Minichart
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal - Stock Titan
Repligen to Acquire BioLife Solutions for $11.25 per Share Plus Stock, Enhancing Cell Processing Capabilities - Kalkine Media
US759916AC3 Bond Profile — Key Metrics - TradingView
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach - Yahoo Finance
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal, Expanding Into Cell Therapy - finance.biggo.com
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal - Kalkine Media
Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share - Kalkine Media
What's Going on With Repligen Stock Wednesday?Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
Repligen Corp: If Deal Terminated Under Some - Moomoo
Repligen to Acquire BioLife Solutions in $1.5 Billion Deal - sekbernews.id
Repligen Corp To Acquire BioLife Solutions Transcript - GuruFocus
Repligen to buy cell therapy maker BioLife in $1.5 billion deal - MSN
Repligen to acquire BioLife Solutions for $1.5 billion - Investing.com
BioLife’s Biopreservation Media Supports 18 Commercially Approved Therapies - Stock Titan
A Look at Repligen Corp (RGEN) After 5.9% Decline -- GF Value $1 - GuruFocus
Why Repligen (RGEN) Stock Is Trading Lower Today - Yahoo Finance
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in cash and stock merger - Stock Titan
Form 4 Repligen Corporation For: 17 July By Investing.com - Investing.com South Africa
Repligen CFO Jason K Garland sells $79,500 in stock - Investing.com UK
Repligen CFO Jason K Garland sells $79,500 in stock By Investing.com - Investing.com Nigeria
Repligen CFO Jason Garland Sells 530 Shares Under Pre-Arranged Rule 10b5-1 Trading Plan - Kalkine Media
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN) - GuruFocus
Repligen (NASDAQ: RGEN) CFO trades 530 shares in 10b5-1 plan sale - Stock Titan
Repligen (RGEN) Stock Looks Fairly Valued On Cash Flow But Fully Priced On Sales - Yahoo Finance
Form 144 REPLIGEN CORP For: 16 July - Investing.com UK
Form 144 REPLIGEN CORP For: 16 July By Investing.com - Investing.com South Africa
Issuer RGEN (NASDAQ: RGEN) plans 530-share sale by Form 144 filer - Stock Titan
RGEN5964422 Bond Profile — Key Metrics - TradingView
0.62%
0.03%
자본화:
|
볼륨(24시간):